Rank-Fc: A therapeutic antagonist for RANK-L in myeloma Review uri icon

Overview

MeSH Major

  • Carrier Proteins
  • Glycoproteins
  • Membrane Glycoproteins
  • Multiple Myeloma
  • Osteoclasts
  • Receptors, Cytoplasmic and Nuclear

abstract

  • MM-induced bone destruction requires increased RANK-L expression and is facilitated by a concurrent reduction in OPG, a natural decoy receptor for RANK-L. Administration of the RANK-L antagonist RANK-Fc limits MM-induced osteoclastogenesis, development of bone disease, and MM tumor progression.

publication date

  • February 2003

Research

keywords

  • Review

Identity

Language

  • eng

PubMed ID

  • 12548579

Additional Document Info

start page

  • 802

end page

  • 12

volume

  • 97

number

  • 3 SUPPL.